Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts.
11/06/2018
Garcia-Doval I, Hernandez MV, Vanaclocha F, Sellas A, de la Cueva P, Montero D, et al.
Descargar documento
Br J Dermatol. 2017 Mar;176(3):643-9.PMID: 27258623